A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Prithviraj Bose, Srdan Verstovsek, Jorge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain, Elias J. Jabbour, Zeev Estrov, Yesid Alvarado, Courtney D. DiNardo, Naveen Pemmaraju, Steven M. Kornblau, Tapan M. Kadia, Naval G. Daver, Kiran Naqvi, Nicholas J. Short, Lucia Masarova, John Villareal, Sherry A. Pierce, Graciela Nogueras-GonzalezXuelin Huang, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi

Research output: Contribution to journalLetter

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)2489-2492
Number of pages4
JournalLeukemia
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bose, P., Verstovsek, S., Cortes, J. E., Tse, S., Gasior, Y., Jain, N., Jabbour, E. J., Estrov, Z., Alvarado, Y., DiNardo, C. D., Pemmaraju, N., Kornblau, S. M., Kadia, T. M., Daver, N. G., Naqvi, K., Short, N. J., Masarova, L., Villareal, J., Pierce, S. A., ... Ravandi, F. (2020). A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 34(9), 2489-2492. https://doi.org/10.1038/s41375-020-0778-0